Summary
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
History
Chimerix was founded in 2000 to discover and develop orally available drugs that target important biological pathways in cancers and other diseases. The company has grown to employ over 70 passionate people who are dedicated to making a meaningful difference for patients. Chimerix has raised over $240 million to date in venture capital and more than $600 million in public and private financing. Chimerix is now publicly trading on the NASDAQ under the symbol CMRX.
Mission
At Chimerix, we are driven by our mission to accelerate the discovery, development and commercialization of oral antivirals and other innovative therapies to improve and save the lives of those living with life-threatening diseases.
Vision
At Chimerix, we are inspired by our vision to become a world-class biopharmaceutical organization that expands patients’ treatment options with life-saving medicines.
Key Team
Mr. David Jakeman CPA (Exec. Director of Fin. & Accounting and Principal Accounting Officer)
Dr. Roy W. Ware (Chief Manufacturing & Technology Officer)
Dr. Randall Lanier (Chief Science Officer)
Dr. Michael A. Alrutz (Sr. VP, Gen. Counsel & Corp. Sec.)
Ms. Michelle LaSpaluto (VP of Strategic Planning & Investor Relations)
Dr. Joshua E. Allen (Chief Technology Officer of Imipridones)
Recognition and Awards
Chimerix has been the recipient of numerous awards and recognition including the North Carolina Biotech Center Award, the Biotechnology Innovation Organization Apollo Awards, and the 2014 FierceBiotech Fierce 15 Award. Chimerix has also been featured in Forbes and Fortune Magazine as one of the top biotech start-ups in the country.
References
